Merrimack Pharmaceuticals Stock Price and Value Analysis

Should you buy Merrimack Pharmaceuticals stock? (NasdaqGM:MACK). Let's see how it does in our automated value investing analysis system.

  • This stock looks overpriced.
  • This company has wild ups and downs.
  • This company is less known than others.
  • This company is not making money.
  • This company pays no dividend.

Inside the MACK Numbers

MACK Price
(Merrimack Pharmaceuticals stock price per share)
[?] PE Ratio versus Sector 224% higher than other Healthcare stocks
[?] PE Ratio versus Industry 13% higher than other Biotechnology stocks
[?] Cash Yield -73.29%
[?] Free Cash Flow Jitter 807%

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 256,562 shares shorted. With 7,360,614 shares available for purchase and an average trading volume over the past 10 trading days of 110,410, it would take at least 2.324 days for all of the short holders to cover their shorts.

Is Merrimack Pharmaceuticals Stock on Sale?

Based on our analysis, we believe that you should not buy Merrimack Pharmaceuticals right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy MACK Stock?

Does Merrimack Pharmaceuticals have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.